Hashes for azuremldataprep-2.4.0-py3-none-any.whl; Algorithm Hash digest; SHA256: acb9978bcd0f8aef46292484ddd9ba098bfe70f8d519695a7a3076: Copy. This page contains a list of all 313 languages for which official Wikipedias have been created under the auspices of the Wikimedia Foundation.This list includes 10 Wikipedias that were closed and moved to the Wikimedia Incubator for further development, so there is a current total of 303 active Wikipedias.

• Meta 1 9 5 Ml To Teaspoons
• Meta 1 9 5 Ml Syringe

The density lead is 11.3 g/mL. What is the mass of 45 mL of the of metal?

1 Answer

Explanation:

Meta 1 9 5 Ml To Teaspoons

For a sample of a substance, the relationship between the mass of the sample and the volume it occupies is given by the density of the substance.

The density of a substance tells you the mass of exactly one unit of volume. In your case, the density of lead is given in #'g mL'^(-1)#, which makes your unit of volume equal to #'1 mL'#.

Meta 1 9 5 Ml Syringe

A density of #'11.3 g mL'^(-1)# means that every unit of volume, i.e. every milliliter, of lead has a mass of #'11.3 g'#.

You know that your sample occupies #'45 mL'#, which implies that it must have a mass of

#45 color(red)(cancel(color(black)('mL'))) * color(white)(overbrace(color(black)('11.3 g'/(1color(red)(cancel(color(black)('mL'))))))^(color(blue)('the density of lead'))) = color(green)( bar(ul(color(white)(a/a)color(black)('510 g')color(white)(a/a) )))#

The answer is rounded to two sig figs.

Related questions

The safe use of METACAM Injection in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating bitches has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been established in dogs with these disorders. Safety has not been established for intramuscular (IM) administration in dogs. When administering METACAM Injection, use a syringe of appropriate size to ensure precise dosing. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease that has not been previously diagnosed.

Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after the administration of the total daily dose of METACAM Oral Suspension, a non-NSAID or noncorticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with METACAM Injection has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of METACAM Injection has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. The effect of cyclo-oxygenase inhibition and the potential for thromboembolic occurrence or a hypercoagulable state has not been studied.